Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Metagenomi, Inc. stock logo
MGX
Metagenomi
$1.32
+3.9%
$1.29
$1.13
$3.95
$47.81M0.69172,562 shs372,441 shs
Moderna, Inc. stock logo
MRNA
Moderna
$67.01
-1.8%
$56.62
$22.28
$85.60
$27.09B0.949.67 million shs8.52 million shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$3.95
-2.2%
$4.15
$1.98
$5.19
$165.34M1.21511,132 shs226,496 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$2.39
-2.0%
$2.12
$1.36
$3.19
$192.57MN/A990,823 shs534,959 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Metagenomi, Inc. stock logo
MGX
Metagenomi
+3.94%+5.60%+10.00%-7.69%-39.45%
Moderna, Inc. stock logo
MRNA
Moderna
-1.85%-18.08%+34.26%+26.82%+99.20%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-2.23%-13.57%+2.07%+3.95%+85.45%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
-2.05%+3.91%+14.35%+1.27%+69.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Metagenomi, Inc. stock logo
MGX
Metagenomi
$1.32
+3.9%
$1.29
$1.13
$3.95
$47.81M0.69172,562 shs372,441 shs
Moderna, Inc. stock logo
MRNA
Moderna
$67.01
-1.8%
$56.62
$22.28
$85.60
$27.09B0.949.67 million shs8.52 million shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$3.95
-2.2%
$4.15
$1.98
$5.19
$165.34M1.21511,132 shs226,496 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$2.39
-2.0%
$2.12
$1.36
$3.19
$192.57MN/A990,823 shs534,959 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Metagenomi, Inc. stock logo
MGX
Metagenomi
+3.94%+5.60%+10.00%-7.69%-39.45%
Moderna, Inc. stock logo
MRNA
Moderna
-1.85%-18.08%+34.26%+26.82%+99.20%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-2.23%-13.57%+2.07%+3.95%+85.45%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
-2.05%+3.91%+14.35%+1.27%+69.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Metagenomi, Inc. stock logo
MGX
Metagenomi
2.80
Moderate Buy$7.00430.30% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.82
Reduce$38.27-42.89% Downside
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
2.00
HoldN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$12.00402.09% Upside

Current Analyst Ratings Breakdown

Latest MGX, MRNA, ORMP, and PLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
UpgradeSell (E+)Sell (D-)
7/8/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetEqual Weight$33.00 ➝ $39.00
7/7/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$38.00 ➝ $45.00
7/7/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Initiated CoverageBuy$7.00 ➝ $5.00
7/7/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetUnderperform$34.00 ➝ $38.00
6/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetOverweight$69.00 ➝ $77.00
6/23/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
DowngradeSell (D-)Sell (E+)
6/18/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingHold
6/12/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingSell (D-)
6/11/2026
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
UpgradeHold (C)Hold (C+)
6/8/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
UpgradeSell (E+)Sell (D-)
(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Metagenomi, Inc. stock logo
MGX
Metagenomi
$25.21M1.97N/AN/A$4.22 per share0.31
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B13.68N/AN/A$22.14 per share3.03
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2M80.84$0.09 per share44.53$5.02 per share0.79
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$76.38M2.52$0.13 per share17.80$0.47 per share5.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$87.87M-$2.30N/AN/AN/A-384.61%-51.23%-36.62%8/11/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$64.05M$2.591.53N/AN/AN/A-5.37%-4.83%8/13/2026 (Estimated)
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.18N/A7.71N/A-21.03%-30.89%-11.74%N/A

Latest MGX, MRNA, ORMP, and PLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.5713N/AN/AN/A$2.76 millionN/A
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.00N/AN/AN/A$103.10 millionN/A
5/11/2026Q1 2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.60-$0.61-$0.01-$0.61$5.90 million$1.25 million
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$0.256.33%N/A9.65%N/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
6.43
6.43
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/A
6.45
6.45
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27

Institutional Ownership

CompanyInstitutional Ownership
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
12.73%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%

Insider Ownership

CompanyInsider Ownership
Metagenomi, Inc. stock logo
MGX
Metagenomi
12.50%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
17.80%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Metagenomi, Inc. stock logo
MGX
Metagenomi
23637.65 million32.94 millionN/A
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
1040.93 million33.64 millionOptionable
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20080.57 million69.00 millionOptionable

Recent News About These Companies

PLX: Chiesi Milestone Received
Protalix: Elfabrio Struggles Against Oral Competition
Protalix: Q4 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Metagenomi stock logo

Metagenomi NASDAQ:MGX

$1.32 +0.05 (+3.94%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$1.32 0.00 (0.00%)
As of 08:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$67.01 -1.26 (-1.85%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$67.80 +0.79 (+1.18%)
As of 08:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Oramed Pharmaceuticals stock logo

Oramed Pharmaceuticals NASDAQ:ORMP

$3.95 -0.09 (-2.23%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$3.92 -0.03 (-0.76%)
As of 08:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$2.39 -0.05 (-2.05%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$2.40 +0.00 (+0.21%)
As of 08:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.